Table 3 Association between patient and treatment characteristics and clinical benefit rate (SD ≥ 6 months/PR/CR) (N = 405*).
Characteristics | Clinical benefit rate (SD ≥ 6 months/PR/CR) | ||||||
|---|---|---|---|---|---|---|---|
Univariate | Multivariate | ||||||
N | SD ≥ 6 months/PR/CR (N, %) | OR (95% CI) | P-value | OR (95% CI) | P-value | ||
Age, years | ≥61 | 207 | 83 (40.1%) | 0.75 (0.50–1.12) | 0.159 | 0.77 (0.51–1.17) | 0.222 |
<61 | 198 | 66 (33.3%) | — | — | — | — | |
Sex | Male | 157 | 54 (34.4%) | 1.18 (0.78–1.80) | 0.427 | — | — |
Female | 248 | 95 (38.3%) | — | — | — | — | |
Matching score (%) | ≥50% | 119 | 62 (52.1%) | 0.40 (0.26–0.62) | <0.001 | 0.40 (0.24–0.67) | <0.001 |
<50% | 286 | 87 (30.4%) | — | — | — | — | |
GI malignancies | Yes | 114 | 35 (30.7%) | 1.45 (0.92–2.31) | 0.113 | — | — |
No | 291 | 114 (39.2%) | — | — | — | — | |
Number of prior lines of therapy | ≥3 | 194 | 60 (30.9%) | 1.63 (1.08–2.45) | 0.019 | 1.51 (1.00–2.30) | 0.052 |
<3 | 211 | 89 (42.2%) | — | — | — | — | |
Immunotherapy-based regimen | Yes | 77 | 35 (45.5%) | 0.64 (0.39–1.06) | 0.081 | 1.12 (0.62–2.03) | 0.709 |
No | 328 | 114 (34.8%) | — | — | — | — | |
